Agile Therapeutics Inc (AGRX) Given Average Recommendation of “Buy” by Brokerages

Agile Therapeutics Inc (NASDAQ:AGRX) has been given an average rating of “Buy” by the eight ratings firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $8.25.

A number of brokerages have recently issued reports on AGRX. HC Wainwright set a $10.00 price target on shares of Agile Therapeutics and gave the company a “buy” rating in a report on Thursday, October 12th. Royal Bank of Canada reiterated a “buy” rating and issued a $10.00 price target on shares of Agile Therapeutics in a report on Wednesday, October 18th. Cantor Fitzgerald reiterated a “buy” rating and issued a $8.00 price target on shares of Agile Therapeutics in a report on Monday, November 20th. Janney Montgomery Scott downgraded shares of Agile Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, December 22nd. Finally, Noble Financial reiterated a “buy” rating on shares of Agile Therapeutics in a report on Thursday, December 28th.

Agile Therapeutics (NASDAQ:AGRX) opened at $3.27 on Friday. The company has a market cap of $111.45, a price-to-earnings ratio of -3.55 and a beta of 2.16. The company has a debt-to-equity ratio of 0.14, a quick ratio of 4.10 and a current ratio of 4.10. Agile Therapeutics has a 12-month low of $1.93 and a 12-month high of $5.60.

Agile Therapeutics (NASDAQ:AGRX) last announced its quarterly earnings results on Monday, November 6th. The specialty pharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.03. sell-side analysts expect that Agile Therapeutics will post -0.97 earnings per share for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Pura Vida Investments LLC grew its stake in Agile Therapeutics by 65.9% in the 3rd quarter. Pura Vida Investments LLC now owns 289,501 shares of the specialty pharmaceutical company’s stock valued at $1,291,000 after acquiring an additional 115,000 shares during the last quarter. Neuberger Berman Group LLC acquired a new stake in Agile Therapeutics in the 3rd quarter valued at about $613,000. Alyeska Investment Group L.P. acquired a new stake in Agile Therapeutics in the 3rd quarter valued at about $3,747,000. Caxton Corp grew its stake in Agile Therapeutics by 12.1% in the 3rd quarter. Caxton Corp now owns 1,820,012 shares of the specialty pharmaceutical company’s stock valued at $8,117,000 after acquiring an additional 196,445 shares during the last quarter. Finally, OxFORD Asset Management LLP acquired a new stake in Agile Therapeutics in the 3rd quarter valued at about $161,000. Institutional investors and hedge funds own 72.89% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was first reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/02/03/agile-therapeutics-inc-agrx-given-average-recommendation-of-buy-by-brokerages.html.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Analyst Recommendations for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply